Affimed
Heidelberg
About Affimed
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $534.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2022)
- Ticker: nasdaq:AFMD
- Website: affimed.com
- Phone: +49 (0)6221-6743-60
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/affimed-106813 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.